{"id":"NCT00758043","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Na誰ve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response","officialTitle":"A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Na誰ve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys速) and Ribavirin (Copegus速)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2010-06","completion":"2010-07","firstPosted":"2008-09-23","resultsPosted":"2011-07-21","lastUpdate":"2021-03-26"},"enrollment":540,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"telaprevir","otherNames":["VX-950"]},{"type":"DRUG","name":"ribavirin","otherNames":["Copegus"]},{"type":"BIOLOGICAL","name":"peginterferon alfa-2a","otherNames":["Pegasys"]}],"arms":[{"label":"T12PR24 (eRVR+)","type":"EXPERIMENTAL"},{"label":"T12PR48 (eRVR+)","type":"EXPERIMENTAL"},{"label":"T12PR48 (eRVR-)","type":"EXPERIMENTAL"},{"label":"Other","type":"EXPERIMENTAL"}],"summary":"This study is being conducted to learn more about the safety and effect of telaprevir in combination with peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) in participants with hepatitis C who have never been treated for their hepatitis C virus (HCV). The study is designed to look at the relative benefits of 24 or 48 weeks of total treatment in people who respond quickly to a telaprevir-based treatment.","primaryOutcome":{"measure":"Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24)","timeFrame":"24 weeks after the last planned dose of study treatment","effectByArm":[{"arm":"T12PR24 (eRVR+)","deltaMin":149,"sd":null},{"arm":"T12PR48 (eRVR+)","deltaMin":140,"sd":null},{"arm":"T12PR48 (eRVR-)","deltaMin":76,"sd":null},{"arm":"Other","deltaMin":23,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":82,"countries":["United States","Belgium","Netherlands","Puerto Rico"]},"refs":{"pmids":["21916639"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":162},"commonTop":["FATIGUE","PRURITUS","NAUSEA","ANAEMIA","HEADACHE"]}}